TW200420543A - Treatment of female sexual dysfunction - Google Patents

Treatment of female sexual dysfunction

Info

Publication number
TW200420543A
TW200420543A TW092130838A TW92130838A TW200420543A TW 200420543 A TW200420543 A TW 200420543A TW 092130838 A TW092130838 A TW 092130838A TW 92130838 A TW92130838 A TW 92130838A TW 200420543 A TW200420543 A TW 200420543A
Authority
TW
Taiwan
Prior art keywords
treatment
female sexual
sexual dysfunction
fsd
fod
Prior art date
Application number
TW092130838A
Other languages
Chinese (zh)
Inventor
Richard James Thurlow
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200420543A publication Critical patent/TW200420543A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates the use of α 1A and/or α 1L adrenergic receptor antagonists for the treatment of female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD) and/or female orgasmic disorder (FOD). The present invention also relates to a method of treatment of FSD, in particular FSAD and/or FOD, as well as to assays to screen for compounds useful in the treatment of FSD, in particular FSAD and/or FOD.
TW092130838A 2002-11-06 2003-11-04 Treatment of female sexual dysfunction TW200420543A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0225908.3A GB0225908D0 (en) 2002-11-06 2002-11-06 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
TW200420543A true TW200420543A (en) 2004-10-16

Family

ID=9947333

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092130838A TW200420543A (en) 2002-11-06 2003-11-04 Treatment of female sexual dysfunction

Country Status (4)

Country Link
AU (1) AU2003274476A1 (en)
GB (1) GB0225908D0 (en)
TW (1) TW200420543A (en)
WO (1) WO2004041259A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2007516949A (en) * 2003-07-16 2007-06-28 ファイザー・インク Treatment of sexual dysfunction
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
ES2336719T3 (en) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh FLIBANSERINE FOR THE TREATMENT OF URINARY INCONTINENCE AND RELATED DISEASES.
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
CA2661613C (en) 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
UY31335A1 (en) 2007-09-12 2009-04-30 VASOMOTOR SYMPTOMS TREATMENT
KR102476626B1 (en) 2014-11-14 2022-12-09 폴리 인터내셔널 System and method for preventing alopecia
US10064816B2 (en) 2015-06-11 2018-09-04 ReJoy Treatment of sexual dysfunction
CN111134894B (en) * 2020-01-17 2022-02-22 上海长海医院 Sampling method for in vivo determination of continuous dynamic free drug concentration of canine prostate tissue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
ES2258300T3 (en) * 1997-12-16 2006-08-16 Pfizer Products Inc. COMBINATION OF ANTAGONISTS OF THE ALFA-1-ADRENERGIC RECEIVER AND A GMPC PDEV INHIBITOR FOR THE TREATMENT OF IMPOTENCE.
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
IT1312310B1 (en) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
IL139455A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
JP2003055261A (en) * 2001-08-08 2003-02-26 Pfizer Prod Inc Combination of preparation
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
AU2003274476A1 (en) 2004-06-07
GB0225908D0 (en) 2002-12-11
WO2004041259A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
TW200420543A (en) Treatment of female sexual dysfunction
IL172357A0 (en) Method for the production of substituted 3-aryl-butyl amine compounds
UA88169C2 (en) Use of peptide compounds for treating pain in trigeminal neuralgia
BRPI0411276A (en) B-cell depletion methods, B-cell neoplasm or malignancy treatment method, B-cell-regulated autoimmune dysfunction relief method, composition and industrialized article
SG157371A1 (en) Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
IL195338A0 (en) Optimized fc variants and methods for their generation
DE60308996D1 (en) melanocortin
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
MX341370B (en) Humanized anti-beta7 antagonists and uses therefor.
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
SG166091A1 (en) Method for producing isocyanates
SG148217A1 (en) Method for treating adamts-5-associated disease
UA99974C2 (en) Method and apparatus for mining and processing seabed sediment
GB0708769D0 (en) Apparatus and method for use in a well bore
MXPA05010855A (en) Method of obtaining galliun-68 and use thereof and device for carrying out saif method.
GB0327380D0 (en) Method
EA200702078A1 (en) METHOD FOR PROCESSING AND CONSTRUCTION OF WELLS
WO2003105772A3 (en) Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
MXPA03003714A (en) Crf receptor antagonists and methods relating thereto.
RS20050887A (en) Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
TW200802178A (en) Reduce the consumption of memory for the image processing
MY142220A (en) Labelled inorganic additives
BRPI0412255A (en) treatment of male sexual dysfunction
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
TW200736207A (en) Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin D3 compounds